《新股消息》普樂師(02486.HK)今起招股 一手入場費2,384元
知名銷售及營銷服務供應商普樂師集團(02486.HK)公布招股詳情,擬全球發售2,500萬股,香港公開發售佔一成,國際配售佔九成。每股招股價介乎10.6至11.8元。每手200股,一手入場費2,383.79元。該股今日(4月28日)起招股,下周四(5月4日)中午截止,預期5月11日掛牌。聯席保薦人為富瑞及國泰君安國際。
如以招股價中位數11.2元計算,公司上市料淨集資約2.27億元,當中約32%擬用於提升核心技術能力及基礎研發;約30%用於戰略投資、收購及合作;約20.5%用於提高銷售及營銷以及業務發展能力;約7.5%用於償還銀行借款;約10%用作營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.